Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Analog Devices, Inc. (ADI) vs TransMedics Group Inc (TMDX) Price & Performance

Analog Devices, Inc.Trade
TransMedics Group IncTrade

Price performance (Past 24H)

Key statistics

Analog Devices, Inc. vs TransMedics Group Inc — how do they compare? Analog Devices, Inc. trades at $385.18 (market cap $187.67B), while TransMedics Group Inc trades at $87.55 (market cap $3.10B). The key difference: Analog Devices, Inc. is far larger — about 60.5× TransMedics Group Inc's market cap, and Analog Devices, Inc. pays a 1.14% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.

ADITMDX
Market Cap
$187.67B$3.10B
Sector
TechnologyTechnology
52-Week High
$445.48$150.42
52-Week Low
$225.20$61.99
Enterprise Value
$192.92B$3.49B
Dividend Yield
1.14%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Analog Devices, Inc.

Analog Devices (ADI) trades at $384.29, up 0.1% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported Q1 2026 EPS of $3.09, exceeding expectations, and maintains strong profitability with a 26.01% net income margin. A dividend of $1.10 per share is scheduled for payment on June 16, 2026, reflecting cash flow stability.

ADI presents a favorable investment case with analyst consensus strongly bullish (79.63% buy ratings) and a price target of $472.29, implying significant upside. Risks include elevated valuation multiples (P/E of 57.34) and semiconductor cycle volatility, but robust fundamentals and AI-driven demand support long-term growth prospects.

TransMedics Group Inc

TransMedics Group (TMDX) trades at $86.43, down 2.24% amid recent earnings misses but maintains strong analyst support with a $99.57 consensus target. The stock shows bullish technical signals with support at $84-87, though RSI levels suggest overbought conditions. Fundamentally, the company demonstrates robust profitability with 58.69% gross margins and 22.69% net income margins, despite recent quarterly earnings falling short of expectations.

Investment outlook remains positive given strong institutional backing and growth potential in organ transplant technology, though risks include ongoing fiduciary investigations and margin pressure from increased operating costs. The stock offers 15% upside to consensus targets but requires monitoring of Q3 earnings performance and legal developments.

Returns comparison

Trailing returns across standard periods

About Analog Devices, Inc.

Analog Devices is a leading analog, mixed signal, and digital signal processing chipmaker. The firm has a significant market share lead in converter chips, which are used to translate analog signals to digital and vice versa. The company serves tens of thousands of customers, and more than half of its chip sales are made to industrial and automotive end markets. Analog Devices' chips are also incorporated into wireless infrastructure equipment.

Read more on ADI

About TransMedics Group Inc

TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.

Read more on TMDX